title: Characteristics of dual specificity phosphatases mRNA regulation by 3,4-methylenedioxymethamphetamine acute treatment in mice striatum.
abstract: 3,4-methylenedioxymethamphetamine (MDMA) is a popular recreational drug that has rewarding properties in rodents but little is known about its effects at the cellular and molecular levels. We have previously shown that the ERK pathway is important for the regulation in gene expression observed in mice striatum after acute treatment with MDMA. Interestingly, three dual specificity phosphatases were found among the genes modulated by MDMA acute treatment. In this study we investigated the signalling pathways leading to the up-regulation of these three mRNAs and the kinetics of their regulation. We found that the increase in Dusp14 mRNA depends on the activation of ERK and lasts longer than those of Dusp1 and Dusp5. The modulation of the three studied Dusps depends partially on the activation of D1 receptors but is independent of the activation of D2 receptors. These results suggest that at least two separate signalling cascades lead to the up-regulation of MAPK phosphatase mRNAs. The increase of Dusp1 and Dusp5 mRNAs is not controlled by ERK activation while that of Dusp14 is a direct negative-feedback mechanism of MDMA-induced ERK signalling. Both mechanisms converge to increase the expression levels of phosphatases able to inactivate ERK.
authors.affiliation: Laboratoire de Neuropsychopharmacologie des addictions (UMR CNRS 7157, INSERM U705) Université Paris Descartes, Faculté de Pharmacie, Paris, France.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Marie-Claire
authors.forename: Nadia
authors.initials: N
authors.lastname: Benturquia
authors.forename: Ann
authors.initials: A
authors.lastname: Lundqvist
authors.forename: Cindie
authors.initials: C
authors.lastname: Courtin
authors.forename: Florence
authors.initials: F
authors.lastname: Noble
mesh_terms: D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects* / Q000201:enzymology / Q000502:physiology; D054638:Dual Specificity Phosphatase 1 / Q000235:genetics / Q000378:metabolism; D054637:Dual-Specificity Phosphatases / Q000235:genetics* / Q000378:metabolism*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006213:Hallucinogens / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D017447:Receptors, Dopamine D1 / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D015854:Up-Regulation / Q000187:drug effects* / Q000502:physiology
chemical_list: D006213:Hallucinogens; D012333:RNA, Messenger; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D048049:Extracellular Signal-Regulated MAP Kinases; D054638:Dual Specificity Phosphatase 1; D054637:Dual-Specificity Phosphatases; C517020:Dusp1 protein, mouse; C498844:Dusp14 protein, mouse; C546197:Dusp5 protein, mouse; D018817:N-Methyl-3,4-methylenedioxyamphetamine